Replies to post #231106 on Avid Bioservices Inc (CDMO)

[irishpark]

it appears there had been a trial for ramucirumab along with docetaxel for HER2-negative, advanced breast cancer which did not produce the expected halt in disease progression.

After a median follow-up of 16.2 months, progression-free survival was 9.5 months in the ramucirumab arm and 8.2 months in the control arm.

Wonder if a combo trial with Bavi thrown in would be beneficial to a study like this.

http://www.news-medical.net/news/20131216/Combination-of-ramucirumab-and-docetaxel-fails-to-delay-advanced-breast-cancer-progression.aspx

[asmarterwookie]

Massachusetts General Hospital and the Sunrise Trial....

http://www.massgeneral.org/cancer/TrialDetails.aspx?p=14-105&disease=Lung+Cancer&nct=NCT01999673

See the bottom of the page...

Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.

I guess Dana Farber knows what's going on....heck...Dana Farber followed me on twitter a long time ago...never got a call for Real Estate...

I see the study start date is December 2013....I know that's when Peregrine announced commencement but this mean MGH started then?

Dear Peregrine, please freak me out in good way....soon.

wook

[biopharm]

Interesting reading this post again as now we see Dr Kathleen Mahoney from Dana Farber....tied into how Dana Farber / Dr Gordon Freeman on recent PS Targeting patents....

I also liked this one

1:35 KEYNOTE PRESENTATION: POLITICS AND REALITIES OF IO COMBINATION TRIAL DESIGN
Llew Keltner, M.D., Ph.D., CEO, EPISTAT
An acute concern of both biotechs and KOLs in IO is getting access to anti-PD-1/PD-L1 from pharma for combination trials. The current state of combination IO trials will be reviewed. The different policies of pharma companies with clinical-stage/marketed anti-PD-1/anti- PD-L1 about access to their compounds for combination trials will be compared. Trial designs and indications that might have decent luck in getting the cooperation of these companies will be suggested.

_________

Combine that with Llew Keltners video below and ties into Heat / Pelican ...where ex analyst Rahul becomes CEO ...and I wonder if Peregrine has something to tell us this week??

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=123186049